Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have received an average recommendation of “Hold” from the nineteen analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $156.8824.

Several equities research analysts have issued reports on the company. Sanford C. Bernstein assumed coverage on Illumina in a research note on Friday, June 26th. They set a “market perform” rating and a $185.00 target price for the company. TD Cowen reiterated a “hold” rating on shares of Illumina in a report on Wednesday, July 15th. Canaccord Genuity Group raised their price objective on Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. Finally, Citigroup upped their target price on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th.

Insider Activity at Illumina

In other news, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the sale, the director directly owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. The trade was a 7.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the transaction, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. This represents a 2.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,003,769 shares of company stock valued at $155,710,908 over the last 90 days. Insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ILMN. HighPoint Advisor Group LLC boosted its holdings in shares of Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after purchasing an additional 80 shares during the last quarter. Elevation Wealth Partners LLC grew its position in shares of Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares during the period. Meeder Advisory Services Inc. increased its stake in Illumina by 3.1% in the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after purchasing an additional 85 shares during the last quarter. Toronto Dominion Bank increased its stake in Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after purchasing an additional 92 shares during the last quarter. Finally, Panagora Asset Management Inc. lifted its position in Illumina by 3.9% during the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after buying an additional 96 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Up 3.1%

Shares of NASDAQ ILMN opened at $196.86 on Friday. The company has a 50 day simple moving average of $170.21 and a 200-day simple moving average of $145.06. The company has a market capitalization of $29.78 billion, a P/E ratio of 35.79, a P/E/G ratio of 2.82 and a beta of 1.47. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina has a 1 year low of $88.00 and a 1 year high of $199.14.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the company earned $0.97 EPS. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities research analysts predict that Illumina will post 5.22 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.